作者
Thérese S Lapperre, Jiska B Snoeck-Stroband, Margot ME Gosman, Désirée F Jansen, Annemarie van Schadewijk, Henk A Thiadens, Judith M Vonk, H Marike Boezen, Nick HT Ten Hacken, Jacob K Sont, Klaus F Rabe, Huib AM Kerstjens, Pieter S Hiemstra, Wim Timens, Dirkje S Postma, Peter J Sterk, GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group*
发表日期
2009/10/20
期刊
Annals of internal medicine
卷号
151
期号
8
页码范围
517-527
出版商
American College of Physicians
简介
Background
Inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs) are used to treat moderate to severe chronic obstructive pulmonary disease (COPD).
Objective
To determine whether long-term ICS therapy, with and without LABAs, reduces inflammation and improves pulmonary function in COPD.
Design
Randomized, placebo-controlled trial. (ClinicalTrials.gov registration number: NCT00158847)
Setting
2 university medical centers in The Netherlands.
Patients
114 steroid-naive current or former smokers with moderate to severe COPD.
Measurements
Cell counts in bronchial biopsies and sputum (primary outcome); methacholine responsiveness at baseline, 6, and 30 months; and clinical outcomes every 3 months …
引用总数
学术搜索中的文章
TS Lapperre, JB Snoeck-Stroband, MME Gosman… - Annals of internal medicine, 2009
